Xcout Intel
Valora Therapeutics, Inc.
Valora Therapeutics, Inc. is a pre-clinical stage biopharmaceutical and biotechnology company based in San Diego, California, pioneering a novel biologic platform to engineer targeted therapies and engage immunity.
Subscribe to see Valora Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Valora Therapeutics, Inc. at a glance
Valora Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $30M in November 2024. Xcout tracks 10 named people at Valora Therapeutics, Inc., including Miguel Garcia-Guzman (CEO).
Valora Therapeutics, Inc. leadership
- Miguel Garcia-GuzmanCEO
- Carolyn BertozziScientific Co-Founder
- Jessica StarkScientific Co-Founder
- James LeeVP, Business Development
- Christine HuhDirector, R&D
- Jad MaamarySr. Director, R&D
4 more named people on record for Valora Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Valora Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $30M | 5 named | |
| SEC Form D filing | $13M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Valora Therapeutics, Inc. competitors
A few of Valora Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.
Amphivena Therapeutics, Inc. is a clinical-stage biotechnology company located in California, United States, focused on immuno-oncology and proprietary T cell engager platforms.
Silverback Therapeutics, Inc. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop therapeutic products.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Get Valora Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Valora Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Valora Therapeutics, Inc. in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access